Search
Check Out Our Sponsors
Latest topics
Role for the epidermal growth factor receptor in chemotherapy-induced alopecia.
Page 1 of 1
Role for the epidermal growth factor receptor in chemotherapy-induced alopecia.
PLoS One. 2013 Jul 19;8(7):e69368. doi: 10.1371/journal.pone.0069368. Print 2013 Jul 22.
Role for the epidermal growth factor receptor in chemotherapy-induced alopecia.
Bichsel KJ, Gogia N, Malouff T, Pena Z, Forney E, Hammiller B, Watson P, Hansen LA.
Department of Biomedical Sciences, School of Medicine, Creighton University, Omaha, Nebraska, United States of America.
Treatment of cancer patients with chemotherapeutics like cyclophosphamide often causes alopecia as a result of premature and aberrant catagen. Because the epidermal growth factor receptor (EGFR) signals anagen hair follicles to enter catagen, we hypothesized that EGFR signaling may be involved in cyclophosphamide-induced alopecia. To test this hypothesis, skin-targeted Egfr mutant mice were generated by crossing floxed Egfr and Keratin 14 promoter-driven Cre recombinase mice. Cyclophosphamide treatment of control mice resulted in alopecia while Egfr mutant skin was resistant to cyclophosphamide-induced alopecia. Egfr mutant skin entered catagen normally, as indicated by dermal papilla condensation and decreased follicular proliferation, but did not progress to telogen as did Egfr wild type follicles. Egfr mutant follicles responded with less proliferation, apoptosis, and fewer p53-positive cells after cyclophosphamide. Treatment of control mice with the EGFR inhibitors erlotinib or gefitinib similarly suppressed alopecia and catagen progression by cyclophosphamide. Secondary analysis of clinical trials utilizing EGFR-targeted therapies and alopecia-inducing chemotherapy also revealed evidence for involvement of EGFR in chemotherapy-induced alopecia. Taken together, our results demonstrated the involvement of EGFR signaling in chemotherapy-induced alopecia, which will help in the design of novel therapeutic regimens to minimize chemotherapy-induced alopecia.
Role for the epidermal growth factor receptor in chemotherapy-induced alopecia.
Bichsel KJ, Gogia N, Malouff T, Pena Z, Forney E, Hammiller B, Watson P, Hansen LA.
Department of Biomedical Sciences, School of Medicine, Creighton University, Omaha, Nebraska, United States of America.
Treatment of cancer patients with chemotherapeutics like cyclophosphamide often causes alopecia as a result of premature and aberrant catagen. Because the epidermal growth factor receptor (EGFR) signals anagen hair follicles to enter catagen, we hypothesized that EGFR signaling may be involved in cyclophosphamide-induced alopecia. To test this hypothesis, skin-targeted Egfr mutant mice were generated by crossing floxed Egfr and Keratin 14 promoter-driven Cre recombinase mice. Cyclophosphamide treatment of control mice resulted in alopecia while Egfr mutant skin was resistant to cyclophosphamide-induced alopecia. Egfr mutant skin entered catagen normally, as indicated by dermal papilla condensation and decreased follicular proliferation, but did not progress to telogen as did Egfr wild type follicles. Egfr mutant follicles responded with less proliferation, apoptosis, and fewer p53-positive cells after cyclophosphamide. Treatment of control mice with the EGFR inhibitors erlotinib or gefitinib similarly suppressed alopecia and catagen progression by cyclophosphamide. Secondary analysis of clinical trials utilizing EGFR-targeted therapies and alopecia-inducing chemotherapy also revealed evidence for involvement of EGFR in chemotherapy-induced alopecia. Taken together, our results demonstrated the involvement of EGFR signaling in chemotherapy-induced alopecia, which will help in the design of novel therapeutic regimens to minimize chemotherapy-induced alopecia.
_________________
My regimen
http://www.immortalhair.org/mpb-regimen
Now available for consultation (hair and/or health)
http://www.immortalhair.org/health-consultation
Similar topics
» Hair growth and epidermal growth factor receptor (EGFR)
» Epidermal Growth Factor Receptor Inhibitors: A Review of Cutaneous Adverse Events and Management.
» Neutralization of IL-8 prevents the induction of dermatologic adverse events associated with the inhibition of epidermal growth factor receptor.
» Histopathologic features of erythematous papulopustular eruption to epidermal growth factor receptor inhibitors in cancer patients.
» Vascular Endothelial Growth Factor Protects CD200-Rich and CD34-Positive Hair Follicle Stem Cells Against Androgen-Induced Apoptosis Through the Phosphoinositide 3-Kinase/Akt Pathway in Patients With Androgenic Alopecia.
» Epidermal Growth Factor Receptor Inhibitors: A Review of Cutaneous Adverse Events and Management.
» Neutralization of IL-8 prevents the induction of dermatologic adverse events associated with the inhibition of epidermal growth factor receptor.
» Histopathologic features of erythematous papulopustular eruption to epidermal growth factor receptor inhibitors in cancer patients.
» Vascular Endothelial Growth Factor Protects CD200-Rich and CD34-Positive Hair Follicle Stem Cells Against Androgen-Induced Apoptosis Through the Phosphoinositide 3-Kinase/Akt Pathway in Patients With Androgenic Alopecia.
Page 1 of 1
Permissions in this forum:
You cannot reply to topics in this forum
Fri May 17, 2024 7:01 am by Atlas
» zombie cells
Sat May 11, 2024 6:54 am by CausticSymmetry
» Sandalore - could it be a game changer?
Wed May 08, 2024 9:45 pm by MikeGore
» *The first scientific evidence in 2021 that viruses do not exist*
Tue May 07, 2024 4:18 am by CausticSymmetry
» China is at it again
Tue May 07, 2024 4:07 am by CausticSymmetry
» Ways to increase adult stem cells
Mon May 06, 2024 5:40 pm by el_llama
» pentadecanoic acid
Sun May 05, 2024 10:56 am by CausticSymmetry
» Exosome Theory and Herpes
Fri May 03, 2024 3:25 am by CausticSymmetry
» Road to recovery - my own log of everything I'm currently trying for HL
Tue Apr 30, 2024 1:55 pm by JtheDreamer